Zomedica (ZOM, $1.80) shares shed -28% on first sale of Truforma
Zomedica's shares have lost around -28% of their value since the company announced the first sale of its Truforma system on March 16.
Truforma is a diagnostic platform for dogs and cats, and is Zomedica's first commercial product. On Nov. 13, Zomedica first announced its plans to commercialize Truforma leading to investors driving the company's stock price by +2,600%! Following the massive rally, many investors apparently decided to take some of their gains off the table on Zomedica's first sale.
Zomedica's announcement of its first sale probably made investors wary of the risks of investing in an early-stage growth company, and therefore they decided to take some of their profits from the stock.
ZOMDF in +3.18% Uptrend, advancing for three consecutive days on May 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZOMDF advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZOMDF as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZOMDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Advertisement
General Information
a company that develops medication for animals
Industry MedicalNursingServices
Advertisement